SteelPeak Wealth LLC Sells 94,279 Shares of Gilead Sciences, Inc. $GILD

SteelPeak Wealth LLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 94.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,158 shares of the biopharmaceutical company’s stock after selling 94,279 shares during the quarter. SteelPeak Wealth LLC’s holdings in Gilead Sciences were worth $573,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC boosted its stake in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences during the second quarter worth approximately $27,000. Putney Financial Group LLC lifted its holdings in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the period. Howard Hughes Medical Institute bought a new position in Gilead Sciences in the second quarter valued at approximately $30,000. Finally, Kilter Group LLC acquired a new stake in Gilead Sciences during the 2nd quarter worth $33,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

GILD stock opened at $121.60 on Friday. Gilead Sciences, Inc. has a 1-year low of $88.57 and a 1-year high of $128.70. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The firm has a market cap of $150.87 billion, a PE ratio of 18.85, a P/E/G ratio of 0.65 and a beta of 0.33. The business’s 50-day moving average price is $123.05 and its two-hundred day moving average price is $117.11.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the prior year, the company earned $2.02 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GILD. BMO Capital Markets set a $135.00 price target on Gilead Sciences in a research note on Tuesday, November 25th. Wolfe Research reiterated an “outperform” rating and issued a $150.00 price objective on shares of Gilead Sciences in a report on Monday, December 15th. Scotiabank assumed coverage on Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 target price on the stock. Truist Financial started coverage on Gilead Sciences in a research report on Monday, November 24th. They set a “buy” rating and a $140.00 target price for the company. Finally, Wells Fargo & Company upped their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $131.68.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares in the company, valued at $13,491,310.98. This represents a 20.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Deborah H. Telman sold 53,646 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the sale, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 136,257 shares of company stock valued at $16,855,192. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.